In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Vera Therapeutics Inc’s stock clocked out at $19.79, up 0.35% from its previous closing price of $19.72. In other words, the price has increased by $0.35 from its previous closing price. On the day, 1.05 million shares were traded. VERA stock price reached its highest trading level at $19.87 during the session, while it also had its lowest trading level at $19.25.
Ratios:
To gain a deeper understanding of VERA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.92 and its Current Ratio is at 16.92. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.16.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $49.Wolfe Research initiated its Outperform rating on February 04, 2025, with a $49 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 23 ’25 when ENRIGHT PATRICK G bought 209,393 shares for $20.87 per share. The transaction valued at 4,369,676 led to the insider holds 3,569,522 shares of the business.
ENRIGHT PATRICK G bought 40,607 shares of VERA for $907,635 on Jun 24 ’25. The Director now owns 3,596,593 shares after completing the transaction at $22.35 per share. On Feb 21 ’25, another insider, Fordyce Marshall, who serves as the PRESIDENT AND CEO of the company, sold 10,613 shares for $27.89 each. As a result, the insider received 296,032 and left with 213,740 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VERA now has a Market Capitalization of 1263071104 and an Enterprise Value of 783795328.
Stock Price History:
The Beta on a monthly basis for VERA is 1.17, which has changed by -0.44782364 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, VERA has reached a high of $51.61, while it has fallen to a 52-week low of $18.53. The 50-Day Moving Average of the stock is -13.42%, while the 200-Day Moving Average is calculated to be -36.24%.
Shares Statistics:
It appears that VERA traded 1.70M shares on average per day over the past three months and 1387400 shares per day over the past ten days. A total of 63.82M shares are outstanding, with a floating share count of 47.69M. Insiders hold about 25.28% of the company’s shares, while institutions hold 89.75% stake in the company. Shares short for VERA as of 1752537600 were 8238798 with a Short Ratio of 4.86, compared to 1749772800 on 9560166. Therefore, it implies a Short% of Shares Outstanding of 8238798 and a Short% of Float of 14.89.
Earnings Estimates
The dynamic stock of Vera Therapeutics Inc (VERA) is currently being evaluated by a team of 3.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$1.15, with high estimates of -$1.0 and low estimates of -$1.24.
Analysts are recommending an EPS of between -$4.03 and -$4.47 for the fiscal current year, implying an average EPS of -$4.31. EPS for the following year is -$3.43, with 6.0 analysts recommending between -$2.28 and -$5.26.
Revenue Estimates
Based on 12 analysts’ estimates, the company’s revenue will be $35.51M in the next fiscal year. The high estimate is $63.54M and the low estimate is $2.57M.
